

SARC SEMIANNUAL MEETING

OON CENTRAL



FRIDAY, MAY 30, 2025 • 7:30 AM-12 NOON CENTRAL

Northwestern Memorial Hospital, Feinberg Conference Center 3rd Floor

251 E. Huron Street, Chicago, IL, USA

SCAN QR CODE FOR MEETING SURVEY

Scott Okuno MD (SARC CMO; Mayo), Seth Pollack MD (Northwestern U.), Steven Young (SARC CEO) 9:00-9:45 am Neoadjuvant Immune Checkpoint Blockade for UPS, Myxofibrosarcoma, and De-Differentiated Liposarcoma: The New Standard of Care? Moderator: Sandra D'Angelo MD (MSKCC) Results of SU2C-SARC032 Ph II RCT Neoadjuvant Pembrolizumab w/RT & Adjuvant Pembrolizumab in STS Debate: Neoadjuvant Immune Checkpoint Blockade for UPS, MFS, and DDLPS Proponent: Nam Bui MD (Stanford U.) Opponent: Nam Bui MD (Stanford U.) Opponent: Aisha Miah MBBS PhD (Royal Marsden) 9:45-10:05 am SARC Studies & Programs Presenters (bolded) Session Chair: Sectt Okuno MD (SARC CMO; Mayo Clinic) <u>SARC-Sponsored Studies:</u> OstaRC 4P hi II Bezuclastinib w/Sunitinib in GIST SARC044 Ph III Bezuclastinib w/Sunitinib in GIST SARC044 Ph III Bezuclastinib w/Sunitinib in GIST SARC044 Ph II Trabectedin w/Irinotecan & 18F-FLT Imaging in ES (PI: Patrick Grohar MD PhD (Co-PI: Royal Marsden) Michael Wagner MD (PI: Dana-Farber Cancer Inst.) Sactt Okuno MD (on behaff of PIs) Sarcoma Centers Directory: Expanded Program Overview Chappie Conrad MD (CHLA); Co-PI: Lara Davis MD (U. of MI)) Sarcoma Centers Directory: Expanded Program Overview Chappie Conrad MD (Chair, SARC Sarcoma Centers Directory Steering Committee) Discussion: Panel & Audience: Kurt Weiss MD (U. of Pittsburgh) Discussion: Panel & Audience: Meena Bedi MD (Medical College of Wisconsin), Abha Gupta MD (Hospital for Sick Children, Princess Margaret Hospital), Rabin Jones MBBS MD (Royal Marsden), Samuel Kim MD (Northwestern U.), Breelyn Wilky MD (U. of Colorado) 11:20-11:25 am Meeting Comments SARC Leadership	7:30-8:55 am	Breakfast & Networking	Feinberg Krumlovsky Atrium	
WD (Northwestern U.), Steven Young (SARC CEO) 9:00-9:45 am Neoadjuvant Immune Checkpoint Blockade for UPS, Myxofibroarcoma, and De-Differentiated Liposarcoma: The New Standard of Care2 Moderator: Sandra D'Angelo MD (MSKCC) Results of SU2C-SARC032 Ph II RCT Neoadjuvant Pembrolizumab w/RT & Adjuvant Pembrolizumab in STS Richard Riedel MD (Duke U.) Debate: Neoadjuvant Immune Checkpoint Blockade for UPS, MFS, and DDLPS Norman Proponent: Nam Bui MD (Stanford U.) Opponent: Aisha Miah MBBS PhD (Royal Marsden) 9:45-10:05 am SARC Studies & Programs SARCO41 Ph III RCT Abemaciclib v. Placebo DDLPS Soft Okuno MD (SARC CMO; Mayo Clinic) SARCO45 Ph II Tebentafusp Advanced CCS SaRC045 Ph II Tebentafusp Advanced CCS SARCO37 Ph II Trabectedin w/Irinotecan & 18F-FLT Imaging in ES (PI: Patrick Grohar MD PhD (U. of NI)) SARC038 Ph II Regorafenib & Nivolumab in OS (PI: Fariba Navid MD (CHLA); Co-PI: Royal Marsden) Sarco33 Ph II Regorafenib & Nivolumab in OS (PI: Fariba Navid MD (CHLA); Co-PI: Carcer Inst.) Sact Okuno MD (on behalf of PIs) Sarco33 Ph II Regorafenib & Nivolumab in OS (PI: Fariba Navid MD (CHLA); Co-PI: Carceracoma Centers Directory Steering Committee) Intervery Steering Committee) 10:05-10:25 am Break Intervery Steering Committee) 0:25-11:20 am Approaches for Sarcoma Patients with Oligometastatic Pu	8:55-9:00 am	Welcome & Opening Remarks	Feinberg ABCD Conference Room	
9:00-9:45 am Neoadjuvant Immune Checkpoint Blockade for UPS, Myxofibrosarcoma, and De-Differentiated Liposarcoma: The New Standard of Care? Moderator: Sandra D'Angelo MD (MSKCC) Results of SU2C-SARC032 Ph II RCT Neoadjuvant Pembrolizumab w/RT & Adjuvant Pembrolizumab in STS Richard Riedel MD (Duke U.) Debate: Neoadjuvant Immune Checkpoint Blockade for UPS, MFS, and DDLPS Proponent: Name Bui MD (Stanford U.) Opponent: View Standard of Care? Neoadjuvant Immune Checkpoint Blockade for UPS, MFS, and DDLPS Prosenters (bolded) Second Chair: SARC Studies & Programs Presenters (bolded) SARC041 Ph III RCT Abemaciclib v. Placebo DDLPS Sart Okuno MD (SARC CMO; Mayo Clinic) SARC042 Ph II Reported Studies: Sart Overviews: SARC043 Ph II Tebentafusp Advanced CCS Madrea Magine MD (PI: Dana-Farber Cancer Inst.) Andrea Napolitano MD PhD (Co-PI: Royal Marsden) Michael Wagner MD (PI: Dana-Farber Cancer Inst.) SARC032 Ph II Trabectedin w/Irinotecan & 18F-FLT Imaging in ES (PI: Patrick Grohar MD PhD (U. of MI)) SARC038 Ph II Regorafenib & Nivolumab in OS (PI: Fariba Navid MD (CHLA); Co-PI: Lara Davis MD (OHSU)) Sarcoma Centers Directory: Expanded Program Overview Chappie Corad MD (Chair, SARC Sarcoma Centers Directory Steering Committee) 10:05-10:25 am Brok Meeting Comments Session Chair: Kurt Weiss MD (U. of Chardo) </th <th></th> <th></th> <th></th>				
De-Differentiated Liposarcoma: The New Standard of Care? Moderator: Sandra D'Angelo MD (MSKCC) Results of SU2C-SARC032 Ph II RCT Neoadjuvant Richard Riedel MD (Duke U.) Pembrolizumab w/RT & Adjuvant Pembrolizumab in STS Proponent: Debate: Neoadjuvant Immune Checkpoint Blockade for UPS, MFS, and DDLPS Proponent: Proponent: Nam Bui MD (Stanford U.) Opponent: Aisha Miah MBBS PhO (Royal Marsden) 9:45-10:05 am SARC Studies & Programs SARCO41 Ph III RCT Abemaciclib v. Placebo DDLPS Sarc O41 Ph III RCT Abemaciclib v. Placebo DDLPS SARC045 Ph II Tebentafusp Advanced CCS Mark Dickson MD (Pl: MSKCC) SARC046 Ph II Nab-Sirolimus in EHE Michael Wagner MD (Pl: Dana-Farber Cancer Inst.) SARC037 Ph II Trabectedin w/Irinotecan & 18F-FLT Imaging in ES (Pl: Patrick Grohar MD PhD (U. of Mil)) SARC038 Ph II Regorafenib & Nivolumab in OS (Pl: Fariba Navid MD (CHLA); Co-Pl: Lara Davis MD (OHSU)) Sarcoma Centers Directory: Expanded Program Overview Chappie Conrad MD (Chair, SARC Sarcoma Centers Directory Steering Committee) 10:05-10:25 am Break 10:25-11:20 am Approaches for Sarcoma Patients with Oligometastatic Pulmonary Disease Session Chair: Kurt Weiss MD (U. of Pittsburgh)				
Moderator: Sandra D'Angelo MD (MSKCC) Results of SU2C-SARC032 Ph II RCT Neoadjuvant Richard Riedel MD (Duke U.) Pembrolizumab w/RT & Adjuvant Pembrolizumab in STS Richard Riedel MD (Duke U.) Debate: Neoadjuvant Immune Checkpoint Blockade for UPS, MFS, and DDLPS Nam Bui MD (Stanford U.) Opponent: Nam Bui MD (Stanford U.) Opponent: Session Chair: SARC-Sponsored Studies: Session Chair: SARC041 Ph III RCT Abemaciclib v. Placebo DDLPS Sect Okuno MD (SARC CMO; Mayo Clinic) SARC044 Ph II Bezuclastinib w/Sunitinib in GIST SARC044 Ph II Bezuclastinib w/Sunitinib in GIST SARC045 Ph II Tebentafusp Advanced CCS Andrea Napolitano MD (Pl: Dana-Farber Cancer Inst.) SARC037 Ph II Trabectedin w/Irinotecan & 18F-FLT Imaging in ES (PI: Patrick Grohar MD PhD (U. of MI)) SArco38 Ph II Regorafenib & Nivolumab in OS (PI: Fariba Navid MD (CHLA); Co-PI: Lara Davis MD (OHSUJ)) Sarcoara Centers Directory: Expanded Program Overview Chappie Conrad MD (Chair, SARC Sarcoma Centers Directory Steering Committee) 10:05-10:25 am Break 10:25-11:20 am Approaches for Sarcoma Patients with Oligometastatic Pulmonary Disease Session Chair: Session Chair: Subcurrent Stream Sarcoare Conterts Sim MD (Nothwestern U.), Breelyn Wilky MD (U. of Colorado) Sarc	9:00-9:45 am			
Results of SU2C-SARC032 Ph II RCT Neoadjuvant Richard Riedel MD (Duke U.) Pembrolizumab w/RT & Adjuvant Pembrolizumab in STS Richard Riedel MD (Duke U.) Debate: Neoadjuvant Immune Checkpoint Blockade for UPS, MFS, and DDLPS Proponent: Nam Bui MD (Stanford U.) Opponent: Aisha Miah MBBS PhD (Royal Marsden) Presenters (bolded) 9:45-10:05 am SARC Studies & Programs 9:45-10:05 am SARC041 Ph III RCT Abemaciclib v. Placebo DDLPS SARC044 Ph II Bezuclastinib w/Sunitinib in GIST Sarcoat Phil Tebentafusp Advanced CCS SARC045 Ph II Tebentafusp Advanced CCS Mark Dickson MD (PI: Dana-Farber Cancer Inst.) SARC037 Ph II Trabectedin w/Irinotecan & 18F-FLT Imaging in ES (PI: Patrick Grohar MD PhD (U. of MI)) SArco38 Ph II Regorafenib & Nivolumab in OS (PI: Fariba Navid MD (CHLA); Co-PI: Lara Davis MD (OHSU)) Sarcoma Centers Directory: Expanded Program Overview Chappie Conrad MD (ChLa); SARC Sarcoma Centers Directory: Expanded Program Overview 10:25-11:20 am Approaches for Sarcoma Patients with Oligometastatic Pulmonary Disease Session Chair: Kurt Weiss MD (U. of Pittsburgh) Discussion: Panel & Audirecce: <t< th=""><th></th><th></th><th></th></t<>				
Pembrolizumab w/RT & Adjuvant Pembrolizumab in STS Debate: Neoadjuvant Immune Checkpoint Blockade for UPS, MFS, and DDLPS Propenent: Nam Bui MD (Stanford U.) Opponent: Aisha Miah MBBS PhD (Royal Marsden) 9:45-10:05 am SARC Studies & Programs Session Chair: Scott Okuno MD (SARC CMO; Mayo Clinic) SARC-Sponsored Studies: Brief Overviews: • SARC041 Ph III RCT Abemaciclib v. Placebo DDLPS Mark Dickson MD (PI: MSKCC) • SARC045 Ph II Bezuclastinib w/Sunitinib in GIST Candace Haddox MD (PI: Dana-Farber Cancer Inst.) • SARC046 Ph II Nab-Sirolimus in EHE Michael Wagner MD (PI: Dana-Farber Cancer Inst.) • SARC037 Ph II Trabectedin w/Irinotecan & 18F-FLT Imaging in ES (PI: Patrick Grohar MD PhD (U. of MI)) Sarcoare Centers Directory: Expanded Program Overview Chappie Conrad MD (Chair, SARC Sarcoma Centers Directory: Expanded Program Overview Session Chair: Discussion: Panel & Audience: Kurt Weiss MD (U. of Pittsburgh) Meeting Comments Session Chair: Kurt Weiss MD (Medical College of Wisconsin), Abfa Gupta MD (Northwestern U.), Breelyn Wilky MD (U. of Colorado) 11:20 -11:20 am Approaches for Sarcoma Patients with Oligometastatic Pulmonary Disease Session Chair: Discussion: Panel & Audience: Kurt Weiss MD (U. of Colorado) 11:20-11:20 am			¥	
Debate: Neoadjuvant Immune Checkpoint Blockade for UPS, MFS, and DDLPS Proponent: Nam Bui MD (Stanford U.) Opponent: Aisha Miah MBBS PhD (Royal Marsden) 9:45-10:05 am SARC Studies & Programs Session Chair: Session Chair: SARC-Sponsored Studies: Soat Okuno MD (SARC CMO; Mayo Clinic) SARC-State Brief Overviews: SARC041 Ph III RCT Abemaciclib v. Placebo DDLPS Mark Dickson MD (PI: MSKCC) SARC044 Ph II Bezuclastinib w/Sunitinib in GIST SARC046 Ph II Nab-Sirolimus in EHE SARC046 Ph II Nab-Sirolimus in EHE Mark Dickson MD (PI: Dana-Farber Cancer Inst.) SARC037 Ph II Trabectedin w/Irinotecan & 18F-FLT Imaging in ES (PI: Patrick Grohar MD PhD (U. of MI)) Sarcoas Centers Directory: Expanded Program Overview Sarcoas Centers Directory: Expanded Program Overview Chappie Conrad MD (Chair, SARC Sarcoma Centers Directory: Expanded Program Overview 10:25-10:25 cm Break 10:25-11:20 am Approaches for Sarcoma Patients with Oligometastatic Pulmonary Disease Session Chair: Kurt Weiss MD (U. of Pittsburgh) Meena Bedi MD (Medical College of Wisconsin), Abha Gupta MD (Hospital for Sick Children, Princess Margaret Hospital), Robin Jones MBBS MD (Royal Marsden), Samuel Kim MD (Northwestern U.), Breelyn Wilky MD (U. of Colorado) 11:20-11:25 am Meeting Co		•	Richard Riedel MD (Duke U.)	
Proponent: Opponent:Nam Bui MD (Stanford U.) Aisha Miah MBBS PhD (Royal Marsden)9:45-10:05 amSARC Studies & ProgramsPresenters (bolded)Session Chair:Scott Okuno MD (SARC CMO; Mayo Clinic)SARC-Sponsored Studies:Brief Overviews:0SARC041 Ph III RCT Abemaciclib v. Placebo DDLPSMark Dickson MD (PI: MSKCC)0SARC044 Ph II Bezuclastinib w/Sunitinib in GISTCandace Haddox MD (PI: Dana-Farber Cancer Inst.)0SARC045 Ph II Tebentafusp Advanced CCSAndrea Napolitano MD PhD (Co-PI: Royal Marsden)0SARC037 Ph II Trabectedin w/Irinotecan & 18F-FLT Imaging in ES (PI: Patrick Grohar MD PhD (U. of MI))0SARC038 Ph II Regorafenib & Nivolumab in OS (PI: Fariba Navid MD (CHLA); Co-PI: Lara Davis MD (OHSU))Sarcona Centers Directory: Expanded Program OverviewChappie Conrad MD (Chair, SARC Sarcoma Centers Directory Steering Committee)10:05-10:25 amBreek10:025-11:20 amApproaches for Sarcoma Patients with Oligometastatic Pulmonary DiseaseSession Chair:Kurt Weiss MD (U. of Pittsburgh)Discussion: Panel & Audience:Kurt Weiss MD (Medical College of Wisconsin), Abha Gupta MD (Hospital for Sick Children, Princess Margaret Hospital), Robin Jones MBBS MD (Royal Marsden), Samuel Kim MD (Northwestern U.), Breelyn Wilky MD (U. of Colorado)11:20-11:25 amMeeting CommentsSARC Leadership11:20-11:25 amMeeting CommentsSARC Leadership11:20-11:25 amMeeting CommentsSARC Leadership11:20-11:25 amMeeting CommentsSARC Leadership11:20-11:25 amMeeting CommentsSARC				
Opponent: Aisha Miah MBBS PhD (Royal Marsden) 9:45-10:05 am SARC Studies & Programs Presenters (bolded) Session Chair: Scott Okuno MD (SARC CMO; Mayo Clinic) SARC-Sponsored Studies: Brief Overviews: • SARC041 Ph III RCT Abemaciclib v. Placebo DDLPS Mark Dickson MD (PI: MSKCC) • SARC044 Ph II Bezuclastinib w/Sunitinib in GIST SARC045 Ph II Tebentafusp Advanced CCS • SARC045 Ph II Tebentafusp Advanced CCS Andrea Napolitano MD PhD (Co-PI: Royal Marsden) • SARC037 Ph II Trabectedin w/Irinotecan & 18F-FLT Imaging in ES (PI: Patrick Grohar MD PhD (U. of MI)) Scott Okuno MD (on behalf of PIs) • SARC038 Ph II Regorafenib & Nivolumab in OS (PI: Fariba Navid MD (CHLA); Co-PI: Lara Davis MD (OHSU)) Sarcoma Centers Directory: Expanded Program Overview Chappie Conrad MD (Chair, SARC Sarcoma Centers Directory Steering Committee) 10:05-10:25 am Break Discussion: Panel & Audience: Meena Bedi MD (Medical College of Wisconsin), Abha Gupta MD (Hospital for Sick Children, Princess Margaret Hospital), Robin Jones MBBS MD (Royal Marsden), Samuel Kim MD (Northwestern U.), Breelyn Wilky MD (U. of Colorado) 11:20-11:25 am Meeting Comments SARC Leadership 11:20-11:25 am Meeting Comments S	Debate: Neoadjuva	•		
9:45-10:05 am SARC Studies & Programs Presenters (bolded) Session Chair: Scott Okuno MD (SARC CMO; Mayo Clinic) SARC-Sponsored Studies: Brief Overviews: SARC041 Ph III RCT Abemaciclib v. Placebo DDLPS Brief Overviews: SARC044 Ph II Bezuclastinib w/Sunitinib in GIST Mark Dickson MD (Pl: MSKCC) SARC045 Ph II Tebentafusp Advanced CCS Andrea Napolitano MD PhD (Co-Pl: Royal Marsden) Michael Wagner MD (Pl: Dana-Farber Cancer Inst.) Andrea Napolitano MD PhD (Co-Pl: Royal Marsden) SARC037 Ph II Trabectedin w/Irinotecan & 18F-FLT Imaging in ES (Pl: Patrick Grohar MD PhD (U. of MI)) Satcotd Sum MD (On behalf of Pls) Sarcona Centers Directory: Expanded Program Overview Chappie Conrad MD (Chair, SARC Sarcoma Centers Directory Steering Committee) 10:05-10:25 am Break 10:25-11:20 am Approaches for Sarcoma Patients with Oligometastatic Pulmonary Disease Session Chair: Kurt Weiss MD (U. of Pittsburgh) Meeting Comments SARC Leadership 11:20-11:25 am Meeting Comments SARC Leadership SARC Leadership 11:20-11:25 am Meeting Comments SARC Leadership SARC Leadership 11:20-11:25 am Meeting Comments SARC Leadership				
Session Chair: Scott Okuno MD (SARC CMO; Mayo Clinic) SARC-Sponsored Studies: Brief Overviews: SARC041 Ph III RCT Abemaciclib v. Placebo DDLPS Mark Dickson MD (Pl: MSKCC) SARC044 Ph II Bezuclastinib w/Sunitinib in GIST SARC045 Ph II Tebentafusp Advanced CCS SARC045 Ph II Tebentafusp Advanced CCS Andrea Napolitano MD PhD (Co-Pl: Royal Marsden) Michael Wagner MD (Pl: Dana-Farber Cancer Inst.) Scott Okuno MD (on behalf of Pls) SARC037 Ph II Trabectedin w/Irinotecan & 18F-FLT Imaging in ES (Pl: Patrick Grohar MD PhD (U. of MI)) Sarcoma Centers Directory: Expanded Program Overview Chappie Conrad MD (Chair, SARC Sarcoma Centers Directory Steering Committee) 10:05-10:25 am Break 10:25-11:20 am Approaches for Sarcoma Patients with Oligometastatic Pulmonary Disease Session Chair: Kurt Weiss MD (U. of Pittsburgh) Discussion: Panel & Audience: Kurt Weiss MD (U. of Pittsburgh) Meena Bedi MD (Medical College of Wisconsin), Abha Gupta MD (Northwestern U.), Breelyn Wilky MD (U. of Colorado) 11:20-11:25 am Meeting Comments SARC Leadership SARC Leadership 11:25 am-12:00 pm CME*: Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive Disease Co-Chairs: Patrick Schöffski MD (Leuven Cancer Institute)		,,	,	
SARC-Sponsored Studies: Sarco Verviews: SARC041 Ph III RCT Abemaciclib v. Placebo DDLPS Mark Dickson MD (PI: MSKCC) SARC044 Ph II Bezuclastinib w/Sunitinib in GIST Sarcout Area Napolitano MD PhD (Co-PI: Royal Marsden) SARC045 Ph II Tebentafusp Advanced CCS Andrea Napolitano MD PhD (Co-PI: Royal Marsden) SARC045 Ph II Tebentafusp Advanced CCS Andrea Napolitano MD PhD (Co-PI: Royal Marsden) SARC045 Ph II Trabectedin w/Irinotecan & 18F-FLT Imaging in ES (PI: Patrick Grohar MD PhD (U. of MI)) Scott Okuno MD (on behalf of PIs) SARC038 Ph II Regorafenib & Nivolumab in OS (PI: Fariba Navid MD (CHLA); Co-PI: Lara Davis MD (OHSU)) Sarcoma Centers Directory: Expanded Program Overview Chappie Conrad MD (Chair, SARC Sarcoma Centers Directory Steering Committee) 10:05-10:25 am Break Session Chair: Kurt Weiss MD (U. of Pittsburgh) Discussion: Panel & Audience: Session Chair: Kurt Weiss MD (U. of Pittsburgh) Meena Bedi MD (Medical College of Wisconsin), Abha Gupta MD (Northwestern U.), Breelyn Wilky MD (U. of Colorado) SARC Leadership 11:25 am-12:00 pm CME*: Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive Disease SarC Leadership 11:25 am-12:00 pm CME*: Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive Disease SarC Leadersh	9:45-10:05 am			
 SARC041 Ph III RCT Abemaciclib v. Placebo DDLPS SARC044 Ph II Bezuclastinib w/Sunitinib in GIST SARC045 Ph II Tebentafusp Advanced CCS SARC046 Ph II Nab-Sirolimus in EHE SARC037 Ph II Trabectedin w/Irinotecan & 18F-FLT Imaging in ES (PI: Patrick Grohar MD PhD (U. of MI)) SARC038 Ph II Regorafenib & Nivolumab in OS (PI: Fariba Navid MD (CHLA); Co-PI: Lara Davis MD (OHSU)) Sarcoma Centers Directory: Expanded Program Overview Chappie Conrad MD (Chair, SARC Sarcoma Centers Directory Steering Committee) 10:05-10:25 am Break Discussion: Panel & Audience: Session Chair: Surt Weiss MD (U. of Pittsburgh) Meeting Comments SARC Gutta MD (Northwestern U.), Breelyn Wilky MD (U. of Colorado) 11:20 am Meeting Comments ChaPti Paniel Kim MD (Leuven Cancer Institute) Break Discussion: Panel & Co-Chairs: Patrick Schöffski MD (Leuven Cancer Institute) Break III Co-Chairs: 		Session Chair:	Scott Okuno MD (SARC CMO; Mayo Clinic)	
 SARC044 Ph II Bezuclastinib w/Sunitinib in GIST SARC045 Ph II Tebentafusp Advanced CCS SARC046 Ph II Nab-Sirolimus in EHE SARC046 Ph II Nab-Sirolimus in EHE SARC037 Ph II Trabectedin w/Irinotecan & 18F-FLT Imaging in ES (PI: Patrick Grohar MD PhD (U. of MI)) SARC038 Ph II Regorafenib & Nivolumab in OS (PI: Fariba Navid MD (CHLA); Co-PI: Lara Davis MD (OHSU)) Sarcoma Centers Directory: Expanded Program Overview Chappie Conrad MD (Chair, SARC Sarcoma Centers Directory Steering Committee) 10:05-10:25 am Break 10:25-11:20 am Approaches for Sarcoma Patients with Oligometastatic Pulmonary Disease Session Chair: Kurt Weiss MD (U. of Pittsburgh) Discussion: Panel & Audience: Meena Bedi MD (Hospital for Sick Children, Princess Margaret Hospital), Robin Jones MBBS MD (Royal Marsden), Samuel Kim MD (Northwestern U.), Breelyn Wilky MD (U. of Colorado) 11:20 am-12:00 pm CME*: Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive Disease Co-Chairs: Patrick Schöffski MD (Leuven Cancer Institute) Breelyn Wilky MD (U. of Colorado) 	SARC-Sponsored S	Studies:	<u>Brief Overviews:</u>	
 SARC045 Ph II Tebentafusp Advanced CCS SARC046 Ph II Nab-Sirolimus in EHE Scott Okuno MD (Pl: Dana-Farber Cancer Inst.) Scott Okuno MD (on behalf of Pls) SARC037 Ph II Trabectedin w/Irinotecan & 18F-FLT Imaging in ES (Pl: Patrick Grohar MD PhD (U. of MI)) SARC038 Ph II Regorafenib & Nivolumab in OS (Pl: Fariba Navid MD (CHLA); Co-Pl: Lara Davis MD (OHSU)) Sarcoma Centers Directory: Expanded Program Overview Chappie Conrad MD (Chair, SARC Sarcoma Centers Directory Steering Committee) 10:05-10:25 am Break 10:25-11:20 am Approaches for Sarcoma Patients with Oligometastatic Pulmonary Disease Session Chair: Session Chair: Kurt Weiss MD (U. of Pittsburgh) Discussion: Panel & Audience: Meena Bedi MD (Medical College of Wisconsin), Abha Gupta MD (Hospital for Sick Children, Princess Margaret Hospital), Robin Jones MBBS MD (Royal Marsden), Samuel Kim MD (Northwestern U.), Breelyn Wilky MD (U. of Colorado) 11:20-11:25 am Meeting Comments CME*: Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive Disease Co-Chairs: Patrick Schöffski MD (Leuven Cancer Institute) Breelyn Wilky MD (U. of Colorado) 	 SARC041 Ph III 	RCT Abemaciclib v. Placebo DDLPS	Mark Dickson MD (PI: MSKCC)	
 SARC046 Ph II Nab-Sirolimus in EHE Michael Wagner MD (PI: Dana-Farber Cancer Inst.) Scott Okuno MD (on behalf of PIs) SARC037 Ph II Trabectedin w/Irinotecan & 18F-FLT Imaging in ES (PI: Patrick Grohar MD PhD (U. of MI)) SARC038 Ph II Regorafenib & Nivolumab in OS (PI: Fariba Navid MD (CHLA); Co-PI: Lara Davis MD (OHSU)) Sarcoma Centers Directory: Expanded Program Overview 	 SARC044 Ph II 	Bezuclastinib w/Sunitinib in GIST	Candace Haddox MD (PI: Dana-Farber Cancer Inst.)	
Scott Okuno MD (on behalf of Pls) • SARC037 Ph II Trabectedin w/Irinotecan & 18F-FLT Imaging in ES (Pl: Patrick Grohar MD PhD (U. of MI)) • SARC038 Ph II Regorafenib & Nivolumab in OS (Pl: Fariba Navid MD (CHLA); Co-Pl: Lara Davis MD (OHSU)) Sarcoma Centers Directory: Expanded Program Overview Chappie Conrad MD (Chair, SARC Sarcoma Centers Directory Steering Committee) 10:05-10:25 am Break 10:25-11:20 am Approaches for Sarcoma Patients with Oligometastatic Pulmonary Disease Session Chair: Kurt Weiss MD (U. of Pittsburgh) Discussion: Panel & Audience: Meena Bedi MD (Medical College of Wisconsin), Abha Gupta MD (Hospital for Sick Children, Princess Margaret Hospital), Robin Jones MBBS MD (Royal Marsden), Samuel Kim MD (Northwestern U.), Breelyn Wilky MD (U. of Colorado) 11:20-11:25 am Meeting Comments SARC Leadership 11:20-11:25 am Meeting Comments SARC Leadership 11:20-11:25 am CME*: Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive Disease Co-Chairs: Co-Chairs: Patrick Schöffski MD (Leuven Cancer Institute) Breelyn Wilky MD (U. of Colorado)	o SARC045 Ph II	Tebentafusp Advanced CCS	Andrea Napolitano MD PhD (Co-PI: Royal Marsden)	
 SARC037 Ph II Trabectedin w/Irinotecan & 18F-FLT Imaging in ES (PI: Patrick Grohar MD PhD (U. of MI)) SARC038 Ph II Regorafenib & Nivolumab in OS (PI: Fariba Navid MD (CHLA); Co-PI: Lara Davis MD (OHSU)) Sarcoma Centers Directory: Expanded Program Overview Chappie Conrad MD (Chair, SARC Sarcoma Centers Directory Steering Committee) 10:05-10:25 am Break 10:25-11:20 am Approaches for Sarcoma Patients with Uigometastatic Pulmonary Disease Session Chair Session: Panel & Audience: Session Chair Discussion: Panel & Audience: Discussion: Panel & Audience: Uigometastatic Pulmonary Disease (Royal Marsden), Samuel Kim MD (Northwestern U.), Breelyn Wilky MD (U. of Colorado) 11:20-11:25 am Meeting Comments SARC Leadership Sarcoma Meeting Comments CME*: Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive Disease Co-Chairs: Patrick Schöffski MD (Leuven Cancer Institute) Breelyn Wilky MD (U. of Colorado) 	o SARC046 Ph II	Nab-Sirolimus in EHE	Michael Wagner MD (PI: Dana-Farber Cancer Inst.)	
 SARC038 Ph II Regorafenib & Nivolumab in OS (PI: Fariba Navid MD (CHLA); Co-PI: Lara Davis MD (OHSU)) Sarcoma Centers Directory: Expanded Program Overview Break 10:05-10:25 am Break 10:25-11:20 am Approaches for Sarcoma Patients with Oligometastatic Pulmonary Disease Session Chair: Discussion: Panel & Audience: Surt Weiss MD (U. of Pittsburgh) Meena Bedi MD (Medical College of Wisconsin), Abha Gupta MD (Hospital for Sick Children, Princess Margaret Hospital), Robin Jones MBBS MD (Royal Marsden), Samuel Kim MD (Northwestern U.), Breelyn Wilky MD (U. of Colorado) 11:20-11:25 am Meeting Comments SARC Leadership 11:25 am-12:00 pm CME*: Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive Disease Co-Chairs: Patrick Schöffski MD (Leuven Cancer Institute) Breelyn Wilky MD (U. of Colorado) 			Scott Okuno MD (on behalf of PIs)	
Sarcoma Centers Directory: Expanded Program Overview Chappie Conrad MD (Chair, SARC Sarcoma Centers Directory Steering Committee) 10:05-10:25 am Break 10:25-11:20 am Approaches for Sarcoma Patients with Oligometastatic Pulmonary Disease Session Chair: Kurt Weiss MD (U. of Pittsburgh) Discussion: Panel & Audience: Meena Bedi MD (Medical College of Wisconsin), Abha Gupta MD (Hospital for Sick Children, Princess Margaret Hospital), Robin Jones MBBS MD (Royal Marsden), Samuel Kim MD (Northwestern U.), Breelyn Wilky MD (U. of Colorado) 11:20-11:25 am Meeting Comments SARC Leadership 11:25 am-12:00 pm CME*: Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive Disease Co-Chairs: Patrick Schöffski MD (Leuven Cancer Institute) Breelyn Wilky MD (U. of Colorado) Breelyn Wilky MD (U. of Colorado)	o SARC037 Ph II Trabectedin w/Irinotecan & 18F-FLT Imaging in ES (PI: Patrick Grohar MD PhD (U. of MI))			
Directory Steering Committee) 10:05-10:25 am Break 10:25-11:20 am Approaches for Sarcoma Patients with Oligometastatic Pulmonary Disease Session Chair: Kurt Weiss MD (U. of Pittsburgh) Discussion: Panel & Audience: Meena Bedi MD (Medical College of Wisconsin), Abha Gupta MD (Hospital for Sick Children, Princess Margaret Hospital), Robin Jones MBBS MD (Royal Marsden), Samuel Kim MD (Northwestern U.), Breelyn Wilky MD (U. of Colorado) 11:20-11:25 am Meeting Comments SARC Leadership 11:25 am-12:00 pm CME*: Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive Disease Co-Chairs: Patrick Schöffski MD (Leuven Cancer Institute) Breelyn Wilky MD (U. of Colorado) Breelyn Wilky MD (U. of Colorado)	• SARC038 Ph II Regorafenib & Nivolumab in OS (PI: Fariba Navid MD (CHLA); Co-PI: Lara Davis MD (OHSU))			
10:05-10:25 am Break 10:25-11:20 am Approaches for Sarcoma Patients with Oligometastatic Pulmonary Disease Session Chair: Kurt Weiss MD (U. of Pittsburgh) Discussion: Panel & Audience: Meena Bedi MD (Medical College of Wisconsin), Abha Gupta MD (Hospital for Sick Children, Princess Margaret Hospital), Robin Jones MBBS MD (Royal Marsden), Samuel Kim MD (Northwestern U.), Breelyn Wilky MD (U. of Colorado) 11:20-11:25 am Meeting Comments SARC Leadership 11:25 am-12:00 pm CME*: Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive Disease Co-Chairs: Patrick Schöffski MD (Leuven Cancer Institute) Breelyn Wilky MD (U. of Colorado)	Sarcoma Centers I	Directory: Expanded Program Overview	Chappie Conrad MD (Chair, SARC Sarcoma Centers	
10:25-11:20 am Approaches for Sarcoma Patients with Oligometastatic Pulmonary Disease Session Chair: Session Chair: Discussion: Panel & Audience: Kurt Weiss MD (U. of Pittsburgh) Meena Bedi MD (Medical College of Wisconsin), Abha Gupta MD (Hospital for Sick Children, Princess Margaret Hospital), Robin Jones MBBS MD (Royal Marsden), Samuel Kim MD (Northwestern U.), Breelyn Wilky MD (U. of Colorado) SARC Leadership 11:25 am-12:00 pm CME*: Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive Disease Co-Chairs: Patrick Schöffski MD (Leuven Cancer Institute) Breelyn Wilky MD (U. of Colorado)		, , , , ,	••	
Session Chair: Kurt Weiss MD (U. of Pittsburgh) Discussion: Panel & Audience: Meena Bedi MD (Medical College of Wisconsin), Abha Gupta MD (Hospital for Sick Children, Princess Margaret Hospital), Robin Jones MBBS MD (Royal Marsden), Samuel Kim MD (Northwestern U.), Breelyn Wilky MD (U. of Colorado) 11:20-11:25 am Meeting Comments SARC Leadership 11:25 am-12:00 pm CME*: Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive Disease Co-Chairs: Patrick Schöffski MD (Leuven Cancer Institute) Breelyn Wilky MD (U. of Colorado)				
Discussion: Panel & Audience: Meena Bedi MD (Medical College of Wisconsin), Abha Gupta MD (Hospital for Sick Children, Princess Margaret Hospital), Robin Jones MBBS MD (Royal Marsden), Samuel Kim MD (Northwestern U.), Breelyn Wilky MD (U. of Colorado) 11:20-11:25 am Meeting Comments SARC Leadership 11:25 am-12:00 pm CME*: Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive Disease Co-Chairs: Patrick Schöffski MD (Leuven Cancer Institute) Breelyn Wilky MD (U. of Colorado)	10:25-11:20 am	Approaches for Sarcoma Patients with (Oligometastatic Pulmonary Disease	
Abha Gupta MD (Hospital for Sick Children, Princess Margaret Hospital), Robin Jones MBBS MD (Royal Marsden), Samuel Kim MD (Northwestern U.), Breelyn Wilky MD (U. of Colorado) 11:20-11:25 am Meeting Comments SARC Leadership 11:25 am-12:00 pm CME*: Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive Disease Co-Chairs: Patrick Schöffski MD (Leuven Cancer Institute) Breelyn Wilky MD (U. of Colorado)		Session Chair:	Kurt Weiss MD (U. of Pittsburgh)	
Princess Margaret Hospital), Robin Jones MBBS MD (Royal Marsden), Samuel Kim MD (Northwestern U.), Breelyn Wilky MD (U. of Colorado)11:20-11:25 amMeeting CommentsSARC Leadership11:25 am-12:00 pmCME*: Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive DiseaseCo-Chairs:Patrick Schöffski MD (Leuven Cancer Institute) Breelyn Wilky MD (U. of Colorado)		Discussion: Panel & Audience:	Meena Bedi MD (Medical College of Wisconsin),	
(Royal Marsden), Samuel Kim MD (Northwestern U.), Breelyn Wilky MD (U. of Colorado) 11:20-11:25 am Meeting Comments SARC Leadership 11:25 am-12:00 pm CME*: Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive Disease Co-Chairs: Patrick Schöffski MD (Leuven Cancer Institute) Breelyn Wilky MD (U. of Colorado)			Abha Gupta MD (Hospital for Sick Children,	
11:20-11:25 am Meeting Comments SARC Leadership 11:25 am-12:00 pm CME*: Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive Disease Co-Chairs: Patrick Schöffski MD (Leuven Cancer Institute) Breelyn Wilky MD (U. of Colorado)			Princess Margaret Hospital), Robin Jones MBBS MD	
11:20-11:25 am Meeting Comments SARC Leadership 11:25 am-12:00 pm CME*: Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive Disease Co-Chairs: Patrick Schöffski MD (Leuven Cancer Institute) Breelyn Wilky MD (U. of Colorado)			(Royal Marsden), Samuel Kim MD (Northwestern	
11:25 am-12:00 pm CME*: Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive Disease Co-Chairs: Patrick Schöffski MD (Leuven Cancer Institute) Breelyn Wilky MD (U. of Colorado)			U.), Breelyn Wilky MD (U. of Colorado)	
Gamma Secretase Inhibitors for Progressive Disease Co-Chairs: Patrick Schöffski MD (Leuven Cancer Institute) Breelyn Wilky MD (U. of Colorado)	11:20-11:25 am	Meeting Comments	SARC Leadership	
Co-Chairs: Patrick Schöffski MD (Leuven Cancer Institute) Breelyn Wilky MD (U. of Colorado)	11:25 am-12:00 pm	CME*: Patient-Centric Frameworks in	Desmoid Tumors: Integrating Emerging Science on	
Breelyn Wilky MD (U. of Colorado)	Gamma Secretase Inhibitors for Progressive Disease			
		Co-Chairs:	Patrick Schöffski MD (Leuven Cancer Institute)	
* This CME activity is provided by PeerView and is separately supported by an independent educational arant from			Breelyn Wilky MD (U. of Colorado)	
SpringWorks Therapeutics, Inc. to PeerView Institute for Medical Education				

Thank You to SARC Semiannual Meeting Sponsors



<u>Silver</u>

<u>Gold</u>



Bronze









